Mr. Nicholas Kadysh reports

PHARMALA RECEIVES NEW "MDXXF" TICKER FROM FINRA FOR OTCQB LISTING

Pharmala Biotech Holdings Inc. has provided an update on its new OTC ticker, MDXXF, which will go into effect on Jan. 24.

"The new ticker symbol more closely aligns with our business model, the research, development and manufacturing of MDXX class molecules," said Nick Kadysh, chief executive officer, Pharmala Biotech. "With less than a month to go before FDA is set to announce its assessment approach for MDMA as a therapeutic molecule, and with Pharmala's globally leading position as an MDMA and MDXX developer, we are more excited than ever for the attention we will be receiving from U.S. audiences in the next few months."

Pharmala will release its Q1 financial statements on Jan. 29, 2024.

About Pharmala Biotech Holdings Inc.

Pharmala Biotech is a biotechnology company focused on the research, development and manufacturing of MDXX class molecules, including MDMA.

We seek Safe Harbor.